Company: RGNT
Filing Date: 2025-10-24
Form Type: F-1/A
Source: 0001213900-25-101900
Chunk: 74

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-10-24
Form: F-1/A
Chunk 74
---
 sales may occur, could cause immediate dilution and adversely affect the market price of our Ordinary Shares.

Future sales of our Ordinary Shares could reduce the market price of our Ordinary Shares.

If our existing shareholders,
particularly our directors, their affiliates, or our executive officers, sell a substantial number of our Ordinary Shares in the public
market, the market price of our Ordinary Shares could decrease significantly. The perception in the public market that our shareholders
might sell our Ordinary Shares could also depress the market price of our Ordinary Shares and could impair our future ability to obtain
capital, especially through an offering of equity securities.

A majority of our Ordinary
Shares outstanding prior to this offering, the Ordinary Shares issuable upon the exercise of warrants and vested options, and Ordinary
Shares which will be issued as a result of the conversion of the 2020 CLAs, the 2024 CLAs and Preferred Shares that will automatically
convert in connection with this offering will be subject to lock-up agreements that restrict the ability of their holders to transfer
such shares for six (6) months after the date of this prospectus. Consequently, upon expiration of the lock-up agreements, the vast majority
of our Ordinary Shares will be eligible for sale in the public market, of which approximately 1,792,058 Ordinary Shares will be subject
to restrictions on volume and manner of sale pursuant to Rule 144 under the Securities Act of 1933, as amended, or the Securities Act.

We have not paid dividends in the past and do not expect to pay dividends in the future, and, as a result, any return on investment may be limited to the value of our shares.

We have never paid cash dividends
and do not anticipate paying cash dividends on our share capital in the foreseeable future. As a result, investors seeking cash dividends
should not purchase our Ordinary Shares. The payment of dividends will depend on our earnings, capital requirements, financial condition,
prospects for future earnings and other factors our board of directors may deem relevant. In addition, our term loan agreement limits
our ability to, among other things, pay dividends or make other distributions or payments on account of our Ordinary Shares, in each
case subject to certain exceptions. If we do not pay dividends, our Ordinary Shares may be less valuable because a return on your investment
will only occur if our share price appreciates and you then sell our Ordinary Shares. In addition, our loan agreements limit our ability
to pay dividends or make other distributions or payments on account of our Ordinary Shares,